- AdventHealth
Clinical Case Study Published in Gynecologic Oncology Reports
Nathalie D. McKenzie, MD
Nnamdi Gwacham, MD
Gynecologic Oncology Program
AdventHealth Cancer Institute
Nnamdi I. Gwacham1, David Ward2, Nathalie D. McKenzie1
1Gynecologic Oncology Program, AdventHealth Cancer Institute, 2Department of Pathology, AdventHealth Orlando, Orlando, FL 32804
Summary
Primary Langerhans cell histiocytosis (LCH) is very rare and is generally encountered more in the childhood and adolescent populations. Its etiology and pathophysiology as well as reliable modes of therapy remain elusive and variable amongst many institutions. It is characterized by proliferation of dendritic cells derived from myeloid precursors. These cells share immunophenotypic and morphologic characteristics with skin Langerhans cells. The disease carries variable presentation and is rarely encountered in the female reproductive tract. When encountered, the vulva is the most common site affected. We report a case of a 31-year-old woman who presented with isolated LCH of the vulva and clitoris that underwent wide local resection and metastatic workup, including robotic-assisted laparoscopic pelvic lymph node dissection and bone marrow biopsy. Metastatic workup was negative, and she remains without recurrence.
Highlights
- Primary vulvar LCH is rare with less than 40 reported cases.
- Diagnosis of vulvar LCH requires prompt metastatic workup to rule out multi-system involvement.
- Treatment protocols for isolated vulvar LCH vary widely, and there is not an established standard of care.
- Continue surveillance is warranted even after prolonged periods of remission.
For more information or to refer a patient, call GYN Oncology Nurse Navigator Althea Buckner, MSN, APRN-AOCNP, at Call407-303-5909.
Read the Case Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134974/
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...
AdventHealth Research Institute and NESTRE Health & Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training
With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...
AdventHealth Among First in U.S. to Offer IDP023-2-101 Clinical Trial for Patients with Progressive Multiple Sclerosis
The AdventHealth Neuroscience Institute is the first in Florida and one of the first in the country to begin recruiting patients with primary progressive or non-active secondary progressive multiple...